Ovarian Clear Cell Carcinoma clinical trials at UCSD
2 research studies open to eligible people
NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
open to eligible people ages 18 years and up
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
La Jolla, California and other locations
Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)
open to eligible females ages 18 years and up
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer).
La Jolla, California and other locations
Our lead scientists for Ovarian Clear Cell Carcinoma research studies include Michael McHale, MD.
Last updated: